Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

No phase data

Trial Status

Completed2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT02751710Not ApplicableCompleted
Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer
Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)
PrincipalinvestigatorStart date: 2016-12-06
NCT02347449Not ApplicableCompleted
The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population
Hormone Receptor Positive Malignant Neoplasm of Breast
PrincipalinvestigatorStart date: 2014-10-01

Research Network

Collaboration Network

29 collaborators·37 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ur Metser, MD

Princess Margaret Hospital, Canada

Related
2 trials

Shared therapeutic areas:

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score24%

Ian Dayes, MD

Juravinski Hospital and Cancer Centre

Related
1 trials

Shared therapeutic areas:

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score24%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

Related
13 trials

Shared therapeutic areas:

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score24%

Ralph George, MD

St. Michael's Hospital, CIBC Breast Centre

Related
1 trials

Shared therapeutic areas:

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score24%

Lea Baer, MD

Stony Brook University

Related
1 trials

Shared therapeutic areas:

Hormone Receptor Positive Malignant Neoplasm of Breast
Similarity Score10%

Thomas Decker, MD

practice based oncology office Ravensburg

Related
1 trials

Shared therapeutic areas:

Hormone Receptor Positive Malignant Neoplasm of Breast
Similarity Score10%

Takayuki Ueno, MD,PhD

Cancer Institute Hospital of JFCR, Department Director, Breast Surgical Oncology Department

Related
1 trials

Shared therapeutic areas:

Hormone Receptor Positive Malignant Neoplasm of Breast
Similarity Score10%

Masakazu Toi, MD,PhD

Kyoto University, Professor of Breast Surgery Department

Related
1 trials

Shared therapeutic areas:

Hormone Receptor Positive Malignant Neoplasm of Breast
Similarity Score10%

Alison Stopeck, MD

Stony Brook University

Related
4 trials

Shared therapeutic areas:

Hormone Receptor Positive Malignant Neoplasm of Breast
Similarity Score10%

Wonshik Han, MD PhD

Seoul National University Hospital

Related
1 trials

Shared therapeutic areas:

Hormone Receptor Positive Malignant Neoplasm of Breast
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT02751710Not ApplicablePrincipalInvestigator

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)
Completed
NCT02347449Not ApplicablePrincipalInvestigator

The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population

Hormone Receptor Positive Malignant Neoplasm of Breast
Completed

All 2 trials loaded